Caliper, Seegene start partnership

Caliper Life Sciences and Seegene will work together to create molecular diagnostic products using the two companies' technology. The products will be co-marketed by the two companies.

Caliper's diagnostic reporting software will be combined with South Korea-based Seegene's diagnostic assays for the products.

"Caliper continues to develop innovative microfluidic solutions that uniquely enable molecular and companion diagnostics," said Kevin Hrusovsky, president and CEO of Caliper Life Sciences, in a release. "This agreement to partner with Seegene's innovative multiplex diagnostic content on the LabChip Dx platform should dramatically improve the economics of diagnostic testing and pave the way for the development of critical diagnostics to accelerate the worldwide implementation of personalized medicine. We believe that Seegene's DPO technology uniquely enables sensitive and specific, highly multiplexed assays directly from clinical samples, significantly improving the economics of today for centralized and hospital based diagnostic testing."

- see the Caliper release
- read the Mass High Tech news

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.